普罗布考联合阿托伐他汀对急性冠状动脉综合征患者近期血脂达标率及预后的影响

The Effect of Probucol and Atorvastatin on Success Rate of Blood Lipids and Prognosis in Acute Coronary Syndrome Patients

目的比较急性冠状动脉综合征患者早期使用普罗布考联合阿托伐他汀与单用阿托伐他汀对近期血脂达标率及预后的影响。方法入选90例急性冠状动脉综合征患者,随机分为单独治疗组(阿托伐他汀20 mg/d,每晚睡前用药一次;n=49)和联合治疗组(普罗布考0.5 g,每天2次;阿托伐他汀20 mg/d,每晚睡前用药一次;n=41)。分别测量两组患者入院和服药1月时血脂水平,并比较两组患者的近期血脂达标率,同时比较两组患者近期不良事件发生情况。结果单独治疗组治疗后血清总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平较治疗前明显降低(P<0.01),高密度脂蛋白胆固醇水平无明显变化。联合治疗组治疗后血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇及高密度脂蛋白胆固醇水平较治疗前明显降低(P<0.01)。两组患者血脂达标率分别为18.4%和48.8%(P<0.01)。两组患者的近期预后差异无显著性。结论普罗布考联合阿托伐他汀与单用阿托伐他汀均可明显降低急性冠状动脉综合征患者近期总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平,联合治疗组同时降低高密度脂蛋白胆固醇水平。普罗布考联合阿托伐他汀较单用阿托伐他汀可明显提高急性冠状动脉综合征患者近期血脂达标率。

Aim To investigate the influences of probucol combined with atorvastatin and solo atorvastatin on success rate of lipid and prognosis in acute coronary syndrome （ACS） patients at 1 month. Methods Ninety ACS patients were assigned to solo atorvastatin group （20 mg/d atorvastatin for 1 month, n = 49） or therapeutic alliance group （20 mg/d atorvastain and 1.0 g/d probucol for 1 month n = 41 ） in a randomized block, controlled study. Serum levels of blood lipids were detected before and aftert teatment. Then prognosis was compared in the two groups. Results The success rate of blood lipids of therapeutic alliance group was higher than solo atorvastatin group, and the prognosis was insignificantly between the two groups. Conclusion Both atorvastatin and probucol may cut down blood lipids in the ACS patients, and atorvastatin combined with probueol can elevate the success rate of blood lipids.